Stada Braces For Battle With Activist Investors
Executive Summary
The interim management of the German generics and OTC firm Stada defends its AGM strategy as Active Ownership Capital rallies troops to fight for greater control of the supervisory board following the temporary departure of its CEO of 23 years.
You may also be interested in...
What Now For Lonely Stada? Bain & Cinven Takeover Bid Collapses
In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Cinven; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.
What Now For Lonely Stada? Bain & Cinven Takeover Bid Collapses
In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Cinven; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.
Cinven's M&A Ambitions Over Stada Under Scrutiny, Advent and Others Circle
By stalking Stada, Cinven seems to be planning to use the German generics group as a base that can support later carve-outs of mature and undervalued products from larger pharma companies - but it faces a rival bidder in Advent, and more suitors could yet appear.